To our knowledge, this is the first reported use of the GLP-1 agonist Liraglutide as an add-on therapeutic intervention in hospitalized patients with COVID-19 pneumonia and supports a rationale for further investigation of the role of CD147 in COVID-19 pathogenesis and its pharmacological modulation relevant to COVID-19 treatment. This evidence concerns the gene GLP1R and COVID-19.